Asset Details
Do you wish to reserve the book?
Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice
Do you wish to request the book?
Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice
2026
Overview
Genetic background is a major determinant of disc degeneration, a leading cause of chronic back pain and disability. Herein, we demonstrate that premature disc cell senescence contributes to early-onset degeneration in SM/J mice and test two systemic senotherapeutic strategies to mitigate it: Navitoclax (Nav.) and a cocktail of Dasatinib and Quercetin (DQ). While Nav. treatment did not improve severe degeneration in SM/J mice or senescence status, DQ-treated mice showed lower grades of degeneration and a decreased abundance of senescence markers, including p19ARF, p21, and the senescence-associated secretory phenotype (SASP). DQ improved disc cell viability and phenotype retention and retarded fibrosis of the nucleus pulposus tissue. Transcriptomic analysis revealed tissue-specific effects of the treatment, with cell cycle regulation and JNK signaling being commonly affected across different tissue types. A comparison of SM/J data with DQ-mediated aging-dependent amelioration of disc degeneration in C57BL/6 N mice identified Junb and Zfp36l1 signaling as shared DQ targets in the mouse disc. Notably, the in vitro inhibition studies of the JUN pathway in human degenerated NP cells mimicked the benefits of DQ, namely, a reduction in senescence and SASP. This study reinforces the efficacy of senolytic treatment in ameliorating local senescence and intervertebral disc fibrosis.
Publisher
Springer Nature B.V,Nature Publishing Group
Subject
/ Animals
/ Cellular Senescence - drug effects
/ Genes
/ Humans
/ Intervertebral Disc Degeneration - drug therapy
/ Intervertebral Disc Degeneration - pathology
/ Kinases
/ Male
/ Mice
/ Nucleus Pulposus - drug effects
/ Nucleus Pulposus - pathology
/ Senotherapeutics - pharmacology
